Vanguard Group’s Lisata Therapeutics LSTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $504K | Buy |
270,909
+395
| +0.1% | +$878 | ﹤0.01% | 3941 |
|
|
2025
Q3 | $709K | Buy |
270,514
+16,332
| +6% | +$41K | ﹤0.01% | 3870 |
|
|
2025
Q2 | $732K | Hold |
254,182
| – | – | ﹤0.01% | 3834 |
|
|
2025
Q1 | $597K | Buy |
254,182
+67,816
| +36% | +$184K | ﹤0.01% | 3839 |
|
|
2024
Q4 | $555K | Hold |
186,366
| – | – | ﹤0.01% | 3923 |
|
|
2024
Q3 | $559K | Buy |
186,366
+2,033
| +1% | +$6.41K | ﹤0.01% | 3945 |
|
|
2024
Q2 | $640K | Buy |
184,333
+2,641
| +1% | +$8.04K | ﹤0.01% | 3925 |
|
|
2024
Q1 | $567K | Buy |
181,692
+4,727
| +3% | +$14K | ﹤0.01% | 3984 |
|
|
2023
Q4 | $483K | Buy |
176,965
+826
| +0.5% | +$1.94K | ﹤0.01% | 4036 |
|
|
2023
Q3 | $377K | Hold |
176,139
| – | – | ﹤0.01% | 4135 |
|
|
2023
Q2 | $652K | Hold |
176,139
| – | – | ﹤0.01% | 4036 |
|
|
2023
Q1 | $572K | Hold |
176,139
| – | – | ﹤0.01% | 4092 |
|
|
2022
Q4 | $446K | Sell |
176,139
-166
| -0.1% | -$609 | ﹤0.01% | 4125 |
|
|
2022
Q3 | $817K | Sell |
176,305
-2
| -0% | -$15 | ﹤0.01% | 4063 |
|
|
2022
Q2 | $1.4M | Sell |
176,307
-3,183
| -2% | -$26.2K | ﹤0.01% | 3968 |
|
|
2022
Q1 | $1.94M | Hold |
179,490
| – | – | ﹤0.01% | 3971 |
|
|
2021
Q4 | $2.27M | Sell |
179,490
-238
| -0.1% | -$3.67K | ﹤0.01% | 3992 |
|
|
2021
Q3 | $3.29M | Sell |
179,728
-141
| -0.1% | -$2.76K | ﹤0.01% | 3881 |
|
|
2021
Q2 | $4.34M | Sell |
179,869
-7,249
| -4% | -$172K | ﹤0.01% | 3666 |
|
|
2021
Q1 | $5.42M | Buy |
187,118
+164,277
| +719% | +$4.98M | ﹤0.01% | 3487 |
|
|
2020
Q4 | $490K | Buy |
22,841
+1,134
| +5% | +$26.9K | ﹤0.01% | 3954 |
|
|
2020
Q3 | $586K | Buy |
21,707
+4,774
| +28% | +$151K | ﹤0.01% | 3783 |
|
|
2020
Q2 | $452K | Buy |
16,933
+682
| +4% | +$20.1K | ﹤0.01% | 3792 |
|
|
2020
Q1 | $439K | Sell |
16,251
-37
| -0.2% | -$1.44K | ﹤0.01% | 3696 |
|
|
2019
Q4 | $613K | Hold |
16,288
| – | – | ﹤0.01% | 3758 |
|
|
2019
Q3 | $618K | Buy |
16,288
+2,423
| +17% | +$94.2K | ﹤0.01% | 3768 |
|
|
2019
Q2 | $474K | Buy |
13,865
+983
| +8% | +$43.7K | ﹤0.01% | 3838 |
|
|
2019
Q1 | $700K | Buy |
12,882
+373
| +3% | +$24.5K | ﹤0.01% | 3712 |
|
|
2018
Q4 | $668K | Sell |
12,509
-996
| -7% | -$69.2K | ﹤0.01% | 3669 |
|
|
2018
Q3 | $1.2M | Buy |
13,505
+380
| +3% | +$31.2K | ﹤0.01% | 3682 |
|
|
2018
Q2 | $1.27M | Buy |
13,125
+628
| +5% | +$44.3K | ﹤0.01% | 3627 |
|
|
2018
Q1 | $1.09M | Buy |
12,497
+5,693
| +84% | +$394K | ﹤0.01% | 3629 |
|
|
2017
Q4 | $358K | Sell |
6,804
-2,943
| -30% | -$148K | ﹤0.01% | 3820 |
|
|
2017
Q3 | $524K | Sell |
9,747
-612
| -6% | -$37.2K | ﹤0.01% | 3738 |
|
|
2017
Q2 | $723K | Buy |
10,359
+278
| +3% | +$19.6K | ﹤0.01% | 3650 |
|
|
2017
Q1 | $761K | Buy |
10,081
+2,843
| +39% | +$197K | ﹤0.01% | 3650 |
|
|
2016
Q4 | $307K | Sell |
7,238
-1,149
| -14% | -$66K | ﹤0.01% | 3820 |
|
|
2016
Q3 | $583K | Sell |
8,387
-452
| -5% | -$36.4K | ﹤0.01% | 3724 |
|
|
2016
Q2 | $783K | Buy |
8,839
+136
| +2% | +$12.5K | ﹤0.01% | 3675 |
|
|
2016
Q1 | $979K | Buy |
8,703
+344
| +4% | +$33.8K | ﹤0.01% | 3606 |
|
|
2015
Q4 | $1.35M | Buy |
8,359
+309
| +4% | +$56.7K | ﹤0.01% | 3531 |
|
|
2015
Q3 | $1.8M | Buy |
8,050
+634
| +9% | +$159K | ﹤0.01% | 3421 |
|
|
2015
Q2 | $2.08M | Buy |
7,416
+1,448
| +24% | +$538K | ﹤0.01% | 3404 |
|
|
2015
Q1 | $2.27M | Buy |
5,968
+412
| +7% | +$223K | ﹤0.01% | 3350 |
|
|
2014
Q4 | $3.14M | Buy |
5,556
+696
| +14% | +$474K | ﹤0.01% | 3108 |
|
|
2014
Q3 | $4.03M | Buy |
4,860
+679
| +16% | +$594K | ﹤0.01% | 2947 |
|
|
2014
Q2 | $4.09M | Buy |
4,181
+333
| +9% | +$324K | ﹤0.01% | 2952 |
|
|
2014
Q1 | $4.07M | Buy |
3,848
+594
| +18% | +$644K | ﹤0.01% | 2932 |
|
|
2013
Q4 | $3.33M | Buy |
3,254
+994
| +44% | +$983K | ﹤0.01% | 2984 |
|
|
2013
Q3 | $2.9M | Buy |
2,260
+32
| +1% | +$35.5K | ﹤0.01% | 2994 |
|
|
2013
Q2 | $1.85M | Buy |
+2,228
| New | +$1.95M | ﹤0.01% | 3089 |
|
Other funds holding LSTA
BCM
GSC
Vanguard Group's LSTA Position: Q4 2025 in Review
Vanguard Group increased its Lisata Therapeutics (LSTA) stake by 0.15% in Q4 2025, buying an estimated $878 and bringing the position to 270,909 shares worth $504K. The position accounts for ﹤0.01% of the portfolio, ranked #3941.
Vanguard Group first reported a position in LSTA in Q2 2013 and has held it in 51 quarters since. The position peaked at $5.42M in Q1 2021. 25 funds tracked by Wall St. Rank hold LSTA as of Q4 2025.
- Vanguard Group held 270,909 shares of Lisata Therapeutics worth $504K as of Q4 2025.
- Vanguard Group bought 395 Lisata Therapeutics shares in Q4 2025, an estimated $878.
- Lisata Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3941 holding.
- Vanguard Group first reported a position in Lisata Therapeutics in Q2 2013 and has held it in 51 quarters since.
- Vanguard Group's Lisata Therapeutics position peaked at $5.42M in Q1 2021.
- 25 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.